ArticleFrontiers in pharmacology2026
Real-world evaluation of attention deficit hyperactivity disorder symptoms and side effects in patients prescribed serdexmethylphenidate/dexmethylphenidate or other stimulants.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) (Azstarys®) is an FDA-approved treatment for ADHD in patients aged 6 years and older. With its prodrug formulation, SDX/d-MPH provides rapid and sustained efficacy. Methods: This study compared the tolerability of SDX/d-MPH with other approved extended-release (ER) stimulant medications by evaluating patient-reported side effects in a real-world sample of patients with ADHD prescribed SDX/d-MPH, lisdexamfetamine (LDX), amphetamine ER (AMP), or methylphenidate ER (MPH). Digital survey responses from 1,395 patients (age: M ± SD = 32.5 ± 14.1 years, range = 7-78 years) treated for ADHD at a single large outpatient psychiatric practice were analyzed. Patients completed the ADHD Symptom and Side Effect Tracking (ASSET) scale in digital pre-visit surveys. Analyses focused on a filtered subset of 697 surveys reflecting early treatment (≤90 days) and ER stimulant monotherapy. Multinomial logistic regressions were conducted to examine associations between side effect frequency and prescription type. Differences in side effect frequency across prescription types were examined using one-way ANOVA with Tukey-adjusted comparisons and ANCOVA controlling for age and time since treatment initiation. To account for within-patient clustering, a MANCOVA including patient as a fixed effect was conducted as a robustness check. Results: Prescription type was associated with all four side effects (all Conclusion: In this single-center retrospective analysis of patient surveys, patients with ADHD taking SDX/d-MPH reported reduced frequency of insomnia compared to AMP ER and LDX, and lower frequency of end-of-dose crash compared to AMP ER. This real-world tolerability analysis highlights the importance of considering side effects in ADHD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.